TeleRanked

Run a telehealth clinic? Claim your profile on TeleRanked.

Business

Eli Lilly and Hims & Hers Strike a Deal to Sell Zepbound and Foundayo Directly on the Telehealth Platform

On November 6, 2026, Eli Lilly and Hims & Hers said eligible patients can buy Lilly's obesity medicines Zepbound and Foundayo directly on the Hims & Hers platform at Lilly's self-pay prices, $299 a month for Zepbound and $149 a month for Foundayo, without leaving the site for LillyDirect. Hims & Hers committed not to sell compounded copies of Lilly's GLP-1 medicines.

The TeleRanked Editors·Updated November 6, 2026·8 min read

Quick answer

On November 6, 2026, Eli Lilly and Hims & Hers announced an agreement that lets eligible patients buy Lilly's FDA-approved obesity medicines, Zepbound and Foundayo, directly on the Hims & Hers telehealth platform after a consultation with a licensed provider. The drugs carry Lilly's self-pay prices, starting at $299 a month for the Zepbound injection and $149 a month for the Foundayo pill, the same prices offered through Lilly's own LillyDirect channel. As part of the deal, Hims & Hers committed not to sell compounded copies or knockoffs of Lilly's GLP-1 medicines.

Key takeaways

  • →Eli Lilly and Hims & Hers announced the agreement on November 6, 2026. Eligible patients can get a prescription from a licensed provider on the Hims & Hers platform and buy Zepbound (tirzepatide) or Foundayo (orforglipron) without leaving the site.
  • →Self-pay pricing starts at $299 a month for Zepbound and $149 a month for Foundayo, matching the prices on Lilly's own LillyDirect platform.
  • →Before this deal, Hims & Hers patients could reach Lilly's drugs only by leaving the platform for LillyDirect, Lilly's cash-pay site.
  • →Hims & Hers has never offered compounded copies of Lilly's GLP-1 medicines and committed not to do so, and the companies said the agreement protects providers' independent clinical decisions.
  • →The deal puts Lilly on the same footing as Novo Nordisk, which has sold Wegovy and Ozempic through Hims & Hers since March 2026.

Eli Lilly and the telehealth company Hims & Hers Health said on November 6, 2026 that they had reached an agreement to sell Lilly's branded obesity medicines directly on the Hims & Hers platform. Eligible patients who receive a prescription from a licensed provider on the platform can now buy Zepbound, Lilly's weekly tirzepatide injection, and Foundayo, Lilly's daily orforglipron pill, and have the medicine shipped to them without leaving the site.

The deal is a commercial distribution arrangement, not a clinical or research finding. It changes how patients on one large weight loss platform reach two FDA-approved drugs, and it brings Lilly into line with its chief rival, Novo Nordisk, which already sells its obesity drugs through the same platform.

What the two companies announced

In a joint announcement, Lilly and Hims & Hers said patients on the Hims & Hers platform can complete a consultation, receive a prescription if a licensed provider judges it appropriate, and purchase Zepbound or Foundayo at Lilly's self-pay prices on the platform itself. Zepbound (tirzepatide) is a once-weekly injection and Foundayo (orforglipron) is a once-daily oral tablet. Both are approved for chronic weight management in adults with obesity, and in adults who are overweight and have at least one weight-related medical condition.

Ilya Yuffa, Executive Vice President and President of Lilly USA and Global Customer Capabilities, said the company is "always looking for new ways to help more people get the medicines they need." Andrew Dudum, co-founder and chief executive of Hims & Hers, described Lilly as "one of the most innovative pharmaceutical companies in history."

How buying the drugs changes for patients

The change is about the path to purchase, not the prescription itself. Before this deal, a Hims & Hers patient who wanted a Lilly obesity drug had to leave the platform and complete the transaction on LillyDirect, Lilly's own cash-pay website. Lilly executives framed that extra step as friction that can cause people to abandon a purchase.

Under the new arrangement, the steps happen in one place:

  • A patient consults a licensed provider on the Hims & Hers platform.
  • If the provider decides the medicine is appropriate, the prescription is written.
  • The patient pays Lilly's self-pay price and the medicine is shipped, all without switching to a separate site.

What the drugs cost on the platform

Both companies said the on-platform prices match Lilly's existing self-pay prices on LillyDirect:

  • Foundayo (orforglipron pill): starting at $149 a month.
  • Zepbound (tirzepatide injection): starting at $299 a month.

These are cash, self-pay prices rather than insured co-pays, and the starting figures apply to specific doses. According to Lilly, about 40 to 45 percent of Zepbound sales are self-pay, which is the slice of the market this arrangement targets. Hims & Hers also sells its own membership and care services alongside the medicine, so a patient's total cost can include fees beyond the drug price.

The commitment on compounded copies

A central term of the deal concerns compounded drugs. Hims & Hers said it has never offered compounded copies of Lilly's GLP-1 medicines and, as part of the agreement, committed not to sell compounded versions or knockoffs of Lilly's obesity drugs. The companies also said the agreement includes protections for independent clinical decision-making, meaning providers on the platform are meant to keep prescribing what they judge appropriate for each patient.

Compounded GLP-1 drugs became widespread during the semaglutide and tirzepatide shortages, and manufacturers have since pressed telehealth firms, in court and through advertising challenges, to stop selling copies now that the branded drugs are available. A no-compounding commitment written into a distribution deal is the commercial counterpart to that pressure.

How this compares with Novo Nordisk

The agreement puts Lilly on equal footing with Novo Nordisk on the Hims & Hers platform. Novo has sold its drugs Wegovy and Ozempic through Hims & Hers since March 2026, an arrangement that followed Novo's earlier lawsuit against the company over compounded versions of its drugs, as Reuters reported. Reuters put Novo's self-pay starting prices at $149 a month for the Wegovy pill and $199 a month for the Wegovy injector pen.

Lilly leads the branded obesity market with Zepbound, while Novo has sold more obesity pills in the United States to date. Lilly launched Foundayo in April 2026, roughly three months after Novo's Wegovy pill reached the market, per Reuters.

What this means

For the two drugmakers, the deal is a distribution play: it meets self-pay customers on a platform where millions already shop for weight-loss care, and it ties that access to a promise not to sell cheaper compounded copies. For Hims & Hers, adding Lilly's full branded lineup alongside Novo's rounds out its GLP-1 menu. Hims & Hers shares rose more than 7 percent in premarket trading on the news, according to Reuters.

For patients, the practical effect is fewer clicks and a clearer price at checkout for two brand-name drugs. It does not lower Lilly's list prices, change insurance coverage, or alter who is clinically eligible for the medicines.

Limits and what is not settled

This is a business agreement between two companies, and the terms described here come from their announcement and from news coverage of it. Prices, available doses, membership fees, and eligibility rules can change, and the starting prices quoted are for self-pay customers at specific doses. Whether a given person should take a GLP-1 drug, and which one, is a medical decision for that person and a licensed clinician. This article is general information, not medical or legal advice. For current prices and terms, check the companies' own platforms, and for drug safety and approved uses, rely on the FDA-approved prescribing information.

Frequently asked questions

What did Eli Lilly and Hims & Hers announce on November 6, 2026?+

They announced an agreement that lets eligible patients buy Lilly's FDA-approved obesity medicines, Zepbound and Foundayo, directly on the Hims & Hers telehealth platform after a consultation with a licensed provider, instead of being sent to Lilly's separate LillyDirect site.

How much do Zepbound and Foundayo cost on the Hims & Hers platform?+

Both companies said the on-platform prices match Lilly's LillyDirect self-pay prices: starting at $299 a month for the Zepbound injection and $149 a month for the Foundayo pill. These are cash, self-pay prices for specific doses, and a patient's total cost may include separate platform or membership fees.

What changed compared with before?+

Before the deal, a Hims & Hers patient who wanted a Lilly obesity drug had to leave the platform and complete the purchase on LillyDirect. Now the consultation, prescription, payment, and shipping can happen on the Hims & Hers platform itself.

Will Hims & Hers still sell compounded versions of these drugs?+

No. Hims & Hers said it has never offered compounded copies of Lilly's GLP-1 medicines and, as part of the agreement, committed not to sell compounded versions or knockoffs of Lilly's obesity drugs.

How does this compare with Novo Nordisk's drugs on the platform?+

The deal puts Lilly on the same footing as Novo Nordisk, which has sold Wegovy and Ozempic through Hims & Hers since March 2026. Reuters reported Novo's self-pay prices starting at $149 a month for the Wegovy pill and $199 a month for the Wegovy injector pen.

Does this deal mean the drugs are cheaper or easier to qualify for?+

No. The agreement changes the purchase path and keeps Lilly's existing self-pay prices. It does not lower list prices, change insurance coverage, or alter clinical eligibility. Whether a GLP-1 drug is appropriate is a decision for a patient and a licensed clinician.

Sources

  1. 1.Lilly to sell obesity drugs directly on Hims & Hers site · Reuters
  2. 2.Lilly and Hims & Hers expand access to FDA-approved Lilly medicines (company announcement) · Chain Drug Review
  3. 3.Lilly Partners with Hims & Hers for Expanded Access · BioPharmaWatch
  4. 4.Lilly partners with Hims & Hers to offer weight-loss drugs · Investing.com

Related